BLEOMYCINE BELLON 15mg powder for injection medication leaflet

L01DC01 bleomycin sulfate • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Other cytotoxic antibiotics

Bleomycinum sulfas is a medication used in the treatment of certain types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, squamous cell carcinoma, and testicular cancer. It belongs to the class of cytotoxic antibiotics and works by damaging the DNA of cancer cells, thereby inhibiting their growth and division.

The medication is usually administered via intravenous, intramuscular, or subcutaneous injection, as directed by a doctor. The dosage and duration of treatment depend on the type of cancer and the patient's overall condition.

Common side effects include fever, chills, nausea, vomiting, and loss of appetite. In rare cases, bleomycinum sulfas can cause pulmonary toxicity, manifested as difficulty breathing or persistent cough, which is why patients must be closely monitored.

Bleomycinum sulfas is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about any other medications they are taking to avoid drug interactions.

General data about BLEOMYCINE BELLON 15mg

Substance: bleomycin sulfate

Date of last drug list: 01-03-2023

Commercial code: W68219001

Concentration: 15mg

Pharmaceutical form: powder for injection

Quantity: 1

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SANOFI AVENTIS DEUTSCHLAND GMBH - GERMANIA

Holder: SANOFI - AVENTIS FRANCE - FRANTA

Number: 668/2021/01

Concentrations available for bleomycin sulfate

15000UI, 15mg

Other substances similar to bleomycin sulfate